Japan Approves First Biotech Generic, For Child Growth Deficiency
This article was originally published in PharmAsia News
Executive Summary
Japanese drug authorities have issued their first approval for a generic version of a biotech drug, Pfizer's Genotropin (somatropin) for treating childhood growth-hormone deficiency. The Novartis unit Sandoz, its generic subsidiary, won the approval, which covers the same range of diseases as the Pfizer drug. The drug also treats growth disturbance caused by chronic renal insufficiency. (Click here for more